Kinesin family member 14: An independent prognostic marker and potential therapeutic target for ovarian cancer

International Journal of Cancer

Volumn 130, Issue 8, 2012, Pages 1844-1854

  Thériault, Brigitte L ^a   Pajovic, Sanja ^a   Bernardini, Marcus Q ^b,c   Shaw, Patricia A ^a,c   Gallie, Brenda L ^a,d,e  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d TORONTO WESTERN HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

KIF14; oncogene; ovarian cancer; prognosis; therapeutic target

Indexed keywords

BIOLOGICAL MARKER; CITRON KINASE; CYCLINE; GENOMIC DNA; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN REGULATING CYTOKINESIS 1; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CELL COUNT; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; ONCOGENE; ONCOGENE KINESIN FAMILY MEMBER 14; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROUS OVARIAN CANCER;

ADENOCARCINOMA, CLEAR CELL; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; DNA COPY NUMBER VARIATIONS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; KINESIN; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84857481599     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26189     Document Type: Article

References (49)

1. Permuth-Wey J, Sellers TA,. Epidemiology of ovarian cancer. Methods Mol Biol 2009; 472: 413-37.
2. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL,. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983; 305: 779-84.
3. Gallie BL, Campbell C, Devlin H, Duckett A, Squire JA,. Developmental basis of retinal-specific induction of cancer by RB mutation. Cancer Res 1999; 59: 1731s-5s.
4. Corson TW, Gallie BL,. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer 2007; 46: 617-34.
5. Dimaras H, Khetan V, Halliday W, Orlic M, Prigoda NL, Piovesan B, Marrano P, Corson TW, Eagle RC, Jr, Squire JA, Gallie BL,. Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet 2008; 17: 1363-72.
6. Godbout R, Dryja TP, Squire J, Gallie BL, Phillips RA,. Somatic inactivation of genes on chromosome 13 is a common event in retinoblastoma. Nature 1983; 304: 451-3.
7. Squire J, Goddard AD, Canton M, Becker A, Phillips RA, Gallie BL,. Tumour induction by the retinoblastoma mutation is independent of N-myc expression. Nature 1986; 322: 555-7.
8. Zhu XP, Dunn JM, Phillips RA, Goddard AD, Paton KE, Becker A, Gallie BL,. Preferential germline mutation of the paternal allele in retinoblastoma. Nature 1989; 340: 312-3.
9. Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, Begley H, Shaw P, Covens A, Murphy J, Rosen B, Minkin S, et al., High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 2005; 7: 603-13.
10. Osterberg L, Levan K, Partheen K, Staaf J, Sundfeldt K, Horvath G,. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma. Cytogenet Genome Res 2009; 125: 8-18.
11. Bruchim I, Israeli O, Mahmud SM, Aviram-Goldring A, Rienstein S, Friedman E, Ben-Baruch G, Gotlieb WH,. Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma. Cancer Genet Cytogenet 2009; 190: 66-70.
12. Caserta D, Benkhalifa M, Baldi M, Fiorentino F, Qumsiyeh M, Moscarini M,. Genome profiling of ovarian adenocarcinomas using pangenomic BACs microarray comparative genomic hybridization. Mol Cytogenet 2008; 1: 10.
13. Corson TW, Huang A, Tsao MS, Gallie BL,. KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers. Oncogene 2005; 24: 4741-53.
14. Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, Choong DY, Campbell IG,. High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 2007; 13: 4731-9.
15. Gras E, Pons C, Machin P, Matias-Guiu X, Prat J,. Loss of heterozygosity at the RB-1 locus and pRB immunostaining in epithelial ovarian tumors: a molecular, immunohistochemical, and clinicopathologic study. Int J Gynecol Pathol 2001; 20: 335-40.
16. Kiechle M, Jacobsen A, Schwarz-Boeger U, Hedderich J, Pfisterer J, Arnold N,. Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. Cancer 2001; 91: 534-40.
17. Kim TM, Yim SH, Shin SH, Xu HD, Jung YC, Park CK, Choi JY, Park WS, Kwon MS, Fiegler H, Carter NP, Rhyu MG, et al., Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer 2008; 123: 2808-15.
18. Staebler A, Karberg B, Behm J, Kuhlmann P, Neubert U, Schmidt H, Korsching E, Burger H, Lelle R, Kiesel L, Bocker W, Shih Ie M, et al., Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes Cancer 2006; 45: 905-17.
19. Szponar A, Zubakov D, Pawlak J, Jauch A, Kovacs G,. Three genetic developmental stages of papillary renal cell tumors: duplication of chromosome 1q marks fatal progression. Int J Cancer 2009; 124: 2071-6.
20. Corson TW, Gallie BL,. KIF14 mRNA expression is a predictor of grade and outcome in breast cancer. Int J Cancer 2006; 119: 1088-94.
21. Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS, Gallie BL,. KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. Clin Cancer Res 2007; 13: 3229-34.
22. Nomura N, Nagase T, Miyajima N, Sazuka T, Tanaka A, Sato S, Seki N, Kawarabayasi Y, Ishikawa K, Tabata S,. Prediction of the coding sequences of unidentified human genes. II. The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of cDNA clones from human cell line KG-1 (supplement). DNA Res 1994; 1: 251-62.
23. Gruneberg U, Neef R, Li X, Chan EH, Chalamalasetty RB, Nigg EA, Barr FA,. KIF14 and citron kinase act together to promote efficient cytokinesis. J Cell Biol 2006; 172: 363-72.
24. Carleton M, Mao M, Biery M, Warrener P, Kim S, Buser C, Marshall CG, Fernandes C, Annis J, Linsley PS,. RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induces cytokinesis failure. Mol Cell Biol 2006; 26: 3853-63.
25. The Atlas of Genetics and Cytogenetics in Oncology and Haematology.
26. Shepherd TG, Theriault BL, Campbell EJ, Nachtigal MW,. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc 2006; 1: 2643-9.
27. Levan K, Partheen K, Osterberg L, Helou K, Horvath G,. Chromosomal alterations in 98 endometrioid adenocarcinomas analyzed with comparative genomic hybridization. Cytogenet Genome Res 2006; 115: 16-22.
28. Rao PH, Harris CP, Yan Lu X, Li XN, Mok SC, Lau CC,. Multicolor spectral karyotyping of serous ovarian adenocarcinoma. Genes Chromosomes Cancer 2002; 33: 123-32.
29. Wang Y, Yang D, Cogdell D, Hu L, Xue F, Broaddus R, Zhang W,. Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma. Technol Cancer Res Treat 2010; 9: 179-89.
30. Li P, Maines-Bandiera S, Kuo WL, Guan Y, Sun Y, Hills M, Huang G, Collins CC, Leung PC, Gray JW, Auersperg N,. Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression. Int J Cancer 2007; 120: 1863-73.
31. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, Bast RC, Jr,. A genetically defined model for human ovarian cancer. Cancer Res 2004; 64: 1655-63.
32. Bowles E, Corson TW, Bayani J, Squire JA, Wong N, Lai PB, Gallie BL,. Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. Genes Chromosomes Cancer 2007; 46: 118-29.
33. Myllykangas S, Bohling T, Knuutila S,. Specificity, selection and significance of gene amplifications in cancer. Semin Cancer Biol 2007; 17: 42-55.
34. Chen S, Leitao MM, Tornos C, Soslow RA,. Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion. Mod Pathol 2005; 18: 903-11.
35. Kobel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB,. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010; 29: 203-11.
36. Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P, Devesa S,. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 2004; 100: 1045-52.
37. Cifone MA, Fidler IJ,. Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci USA 1980; 77: 1039-43.
38. Kang JS, Krauss RS,. Ras induces anchorage-independent growth by subverting multiple adhesion-regulated cell cycle events. Mol Cell Biol 1996; 16: 3370-80.
39. Jiang Y, Cui L, Yie TA, Rom WN, Cheng H, Tchou-Wong KM,. Inhibition of anchorage-independent growth and lung metastasis of A549 lung carcinoma cells by IkappaBbeta. Oncogene 2001; 20: 2254-63.
40. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC,. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001; 22: 255-88.
41. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y,. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007; 19: 3-9.
42. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, et al., Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008; 5: e232.
43. Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA, Jr, Vogelstein B, Kinzler KW, Velculescu VE, et al., Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-31.
44. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, et al., ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-43.
45. Hirokawa N, Noda Y,. Intracellular transport and kinesin superfamily proteins, KIFs: structure, function, and dynamics. Physiol Rev 2008; 88: 1089-118.
46. Jani JP, Arcari J, Bernardo V, Bhattacharya SK, Briere D, Cohen BD, Coleman K, Christensen JG, Emerson EO, Jakowski A, Hook K, Los G, et al., PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther 2010; 9: 883-94.
47. Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, Chang S, Multani AS, et al., Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res 2010; 16: 3171-81.
48. Cohen RB, Jones SF, Aggarwal C, von Mehren M, Cheng J, Spigel DR, Greco FA, Mariani M, Rocchetti M, Ceruti R, Comis S, Laffranchi B, et al., A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hr infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 6694-701.
49. Fu Y, Huang J, Wang KS, Zhang X, Han ZG,. RNA interference targeting CITRON can significantly inhibit the proliferation of hepatocellular carcinoma cells. Mol Biol Rep 2011; 38: 693-702.